An e-mail, from Mark Merritt, president and CEO of the trade group Pharmaceutical Care Management Association, to the organization’s board, lays out a plan to develop an aggressive campaign to convince the new administration that the fault rests with pharmaceutical manufacturers.
The blame game of who is responsible for jacking up drug prices is at the cusp of turning into a full-blown war. A leaked e-mail, from Mark Merritt, president and CEO of the trade group Pharmaceutical Care Management Association (PCMA), to the organization’s board, lays out a plan to develop an aggressive campaign to convince the new administration that the fault rests with pharmaceutical manufacturers.
The e-mail, which was sent to the board in the first week of February, states that PCMA plans to develop a hardline strategy that will involve the Trump administration and “counter efforts to undermine PBMs’ [pharmacy benefit managers’] ability to reduce cost for payers and consumers.” The organization is trying to fast-track this process rather than go the traditional route of presenting a strategic update once key officials and new policies were in place, because they are unsure of the responses from a nonconventional presidency that does not seem to have faith in a deliberative process.
The 6-point plan that Merritt presented to the board lists the following strategies:
6. Mobilizing pro-payer allies and policy solutions. Efforts are on to align with health plans on their approach to the drug price issue. This will include conversations with the America’s Health Insurance Plans, The American Action Forum, and others.
Referencing the recent meetings between top drug manufacturers and the president, Merritt states in his e-mail that the blame was placed squarely on “bloated supply chains.” In a separate meeting of Stephen J. Ubl, CEO of the Pharmaceutical Researchers of Manufacturers America (PhRMA) and 6 members of the PhRMA board with President Donald Trump, the following strategies for drug price reduction were discussed:
Meanwhile, underscoring the urgency of the issue at hand, Merritt wrote that it is important that “we cut through the clutter and make our case as vocally and effectively as possible.”
PBMs have been accused of implementing practices that drive up drug prices. A recent white paper commissioned by the Community Oncology Alliance, for example, blamed PBMs of administering direct and indirect remuneration, or DIR, fees that inflate prices for Medicare Part D beneficiaries. PCMA out rightly denied the report’s findings.